爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EW 爱德华兹

休市中 08-21 16:00:00 EDT

89.79

-0.04

-0.04%

盘后89.79

+0.000.00%

19:52 EDT

最高90.37	最低88.79	成交量281.98万
今开89.89	昨收89.83	日振幅1.76%
总市值517.68亿	流通市值516.32亿	总股本5.77亿
成交额2.53亿	换手率0.49%	流通股本5.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EW","market":"US","secType":"STK","nameCN":"爱德华兹","latestPrice":89.79,"timestamp":1787342400000,"preClose":89.83,"halted":0,"volume":2819775,"hourTrading":{"tag":"盘后","latestPrice":89.79,"preClose":89.79,"latestTime":"19:52 EDT","volume":80781,"amount":7253323.377,"timestamp":1787356359593,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00044528553935202096,"floatShares":575029897,"shares":576541693,"eps":1.719085,"marketStatus":"休市中","change":-0.04,"latestTime":"08-21 16:00:00 EDT","open":89.89,"high":90.37,"low":88.79,"amount":253155282.6285,"amplitude":0.017589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.719085,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":89.83,"preHourTrading":{"tag":"盘前","latestPrice":89.83,"preClose":89.83,"latestTime":"09:17 EDT","volume":243,"amount":21785.869998,"timestamp":1787318245802,"change":0,"changeRate":0,"amplitude":0.018529},"postHourTrading":{"tag":"盘后","latestPrice":89.79,"preClose":89.79,"latestTime":"19:52 EDT","volume":80781,"amount":7253323.377,"timestamp":1787356359593,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0135955577241886,"impliedVol":0.2562,"impliedVolPercentile":0.251},"requestUrl":"/m/hq/s/EW","defaultTab":"news","newsList":[{"id":"1138688907","title":"异动解读｜爱德华兹生命科学盘中上涨3.1%，多家投行密集上调评级及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1138688907","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138688907?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:05","pubTimestamp":1785780304,"startTime":"0","endTime":"0","summary":"8月4日，爱德华兹生命科学盘中上涨3.1%，报88.74美元/股，成交额1.62亿美元。消息面上，近期多家华尔街投行密集上调公司评级及目标价。基本面方面，公司二季度调整后每股收益0.78美元，超出市场预期的0.74美元；营收17.41亿美元，同比增长13.7%，超出预期的17.00亿美元。此外，医疗保健设备板块整体走强，板块内直觉外科涨5.78%、史赛克涨4.06%，形成联动效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168381492","title":"异动解读｜爱德华兹生命科学盘中上涨6.05%，Q2业绩全面超预期且上调TAVR增长指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1168381492","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168381492?lang=zh_cn&edition=full","pubTime":"2026-07-24 21:32","pubTimestamp":1784899975,"startTime":"0","endTime":"0","summary":"7月24日，爱德华兹生命科学盘中上涨6.05%，报88.615美元/股。消息面上，公司发布第二季度财报，调整后每股收益0.78美元，超出市场预期的0.74美元，同比增长16.4%；营收17.41亿美元，高于预期的17.00亿美元，同比增长13.7%。核心产品TAVR本季度销售额达12.6亿美元，同比增长11.3%，超出市场预期。公司同时将全年TAVR销售增长预期下限从7%上调至8%。此外，Leerink Partners将公司评级从\"与大盘持平\"上调至\"跑赢大盘\"，目标价从87美元提高至101美元，进一步提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171822599","title":"Leerink Partners上调爱德华兹评级至跑赢大盘，目标价从87美元升至101美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171822599","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171822599?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:30","pubTimestamp":1784889022,"startTime":"0","endTime":"0","summary":"华尔街投行Leerink Partners调整了对爱德华兹生命科学的评级，将该公司股票从“与大盘持平”上调至“跑赢大盘”。与此同时，分析师还将目标股价从原先的87美元提高至101美元。这一动作反映出机构对爱德华兹未来前景的乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0345774631.USD","BMED","LU0289739699.SGD","SG9999013999.USD","IE00BN0W2T93.GBP","BK4588","BK4567","AGNG","BK4082","SG9999001176.USD","IE00BN0W2V16.EUR","EW","IHI","SGXZ57979304.SGD","BK4585","SG9999001176.SGD","IE00BYQQ9H92.USD","LU0823416689.USD","IE00BFXG0V08.USD","LU0345774391.USD","BK4504","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150697291","title":"异动解读｜爱德华兹生命科学夜盘上涨5.57%，Q2业绩全面超预期且上调TAVR增长指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1150697291","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150697291?lang=zh_cn&edition=full","pubTime":"2026-07-24 15:26","pubTimestamp":1784877992,"startTime":"0","endTime":"0","summary":"7月24日，爱德华兹生命科学夜盘上涨5.57%，报88.49美元/股。消息面上，公司发布第二季度财报，业绩全面超出市场预期。核心产品TAVR本季度销售额达12.6亿美元，同比增长11.3%，超出市场预期的12.3亿美元。公司同时将全年TAVR销售增长预期下限从7%上调至8%，并维持全年调整后每股收益2.95至3.05美元的指引。爱德华兹生命科学在结构性心脏病及重症监护领域处于全球领先地位，专注于人工心脏瓣膜等创新疗法的研发与商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157520890","title":"异动解读 | 爱德华兹生命科学夜盘大涨5.76%，Q2业绩超预期且TAVR需求强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1157520890","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157520890?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:30","pubTimestamp":1784874644,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学（EW）在夜盘交易中股价大涨5.76%，引发市场关注。消息面上，公司公布了超出预期的第二季度业绩。得益于用于复杂心脏手术的人工心脏瓣膜需求强劲，其季度利润和营收均高于分析师预期。具体来看，核心产品经导管主动脉瓣置换装置（TAVR）本季度销售额同比增长11.3%，达到12.6亿美元，远超市场预期的12.3亿美元。此外，公司还将2026年TAVR设备销售额增长预期的下限从7%上调至8%，并维持了年度调整后利润预期。强劲的业绩和乐观的指引共同推动了股价在夜盘时段走高。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144791790","title":"财报前瞻｜爱德华兹本季度营收预计增14.19%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1144791790","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144791790?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:47","pubTimestamp":1784162840,"startTime":"0","endTime":"0","summary":"爱德华兹将于2026年07月23日（盘后）发布新一季度财报，市场聚焦经导管瓣膜需求与政策催化下的量价变化及利润韧性。市场一致预期本季度爱德华兹营收为17.00亿美元，同比增长14.19%；EBIT为4.79亿美元，同比增长17.60%；调整后每股收益为0.74美元，同比增长18.99%。上季度公司营收16.49亿美元，同比增长16.70%；毛利率78.01%；归属于母公司股东的净利润3.81亿美元；净利率23.09%；调整后每股收益0.78美元，同比增长21.88%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜爱德华兹本季度营收预计增14.19%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118580893","title":"异动解读｜爱德华兹盘中下跌3.21%，报87.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118580893","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118580893?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:49","pubTimestamp":1784123395,"startTime":"0","endTime":"0","summary":"7月15日，爱德华兹盘中下跌3.21%，报87.25美元/股，成交额3816.34万美元。爱德华兹所在的医疗保健设备行业中，个股表现分化，其中直觉外科公司跌0.03%，雅培跌0.56%，美敦力涨0.39%，史赛克涨0.01%，波士顿科学跌0.84%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125263351","title":"异动解读｜爱德华兹盘中下跌3.28%，报89.915美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125263351","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125263351?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:11","pubTimestamp":1784038296,"startTime":"0","endTime":"0","summary":"7月14日，爱德华兹盘中下跌3.28%，报89.915美元/股，成交额8200.87万美元。爱德华兹所在的医疗保健设备行业中，个股普遍承压，其中直觉外科公司跌3.96%，史赛克跌5.67%，雅培跌2.5%，波士顿科学跌3.67%，美敦力跌3.73%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193798413","title":"异动解读｜爱德华兹盘中上涨3.53%，CMS发布TAVR国家覆盖决定备忘录持续构成利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1193798413","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193798413?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:01","pubTimestamp":1782309667,"startTime":"0","endTime":"0","summary":"6月24日，爱德华兹盘中上涨3.53%，报90.3美元/股，成交额5171.11万美元。消息面上，CMS此前发布TAVR国家覆盖决定备忘录，加拿大皇家银行指出该备忘录是爱德华兹的重要催化剂，其医师调研显示覆盖范围变更可推动全国手术量增长约5%，单操作员模式转变对手术效率提升最为显著，同时伴随手术场所扩展。爱德华兹所在的医疗保健设备行业中，史赛克涨2.48%，雅培涨2.31%，直觉外科公司涨1.2%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178883749","title":"异动解读｜爱德华兹盘中上涨3.51%，CMS发布TAVR国家覆盖决定备忘录构成利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1178883749","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178883749?lang=zh_cn&edition=full","pubTime":"2026-06-17 00:13","pubTimestamp":1781626411,"startTime":"0","endTime":"0","summary":"6月17日，爱德华兹盘中上涨3.51%，报89.31美元/股，成交额2.57亿美元。加拿大皇家银行此前指出，该备忘录是爱德华兹的重要催化剂，其医师调研显示覆盖范围变更可推动全国手术量增长约5%，单操作员模式转变对手术效率提升最为显著，同时伴随手术场所扩展。爱德华兹所在的医疗保健设备行业中，雅培涨1.07%，美敦力涨0.91%，史赛克涨0.43%，直觉外科公司涨0.14%，波士顿科学跌0.4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476002","title":"Sensor Tower：《王者荣耀》跃升至全球手游收入榜榜首","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476002","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634476002?lang=zh_cn&edition=full","pubTime":"2026-05-11 11:50","pubTimestamp":1778471403,"startTime":"0","endTime":"0","summary":"《王者荣耀》在2026年4月跃升至全球手游收入榜榜首。紧随其后的是《Last War: Survival Game》、《Whiteout Survival》、《Royal Match》以及《Gossip Harbor》，共同跻身全球收入榜前五。2026年4月全球手游下载排行榜 TOP 10根据 Sensor Tower 应用表现洞察最新数据，《王者荣耀》在2026年4月位列全球手游收入榜榜首，这主要得益于其强劲且密集的运营活动。《SD Gundam G Generation ETERNAL》在1周年重大更新的推动下，荣登4月份全球手游收入增长榜榜首。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EW","LU0345774391.USD","BK4585","SGXZ57979304.SGD","BK4504","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999001176.USD","LU0345774631.USD","BK4082","BK4588","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","SG9999001176.SGD","SG9999013999.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630388345","title":"华泰通信: 光纤光缆进入历史大周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630388345","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630388345?lang=zh_cn&edition=full","pubTime":"2026-04-26 08:37","pubTimestamp":1777163820,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　25Q4以来，全球光纤光缆市场呈现“量价共振”态势。我们认为本轮光纤光缆景气周期的核心驱动力在于供给需求关系重构。市场认为光纤价格上涨会引发企业大规模扩产，而我们认为行业未来2年内新增有效供给有限，景气周期有望拉长。基于此，我们看好本轮需求周期高度与持续性有望超过上轮。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-26/doc-inhvupep0143387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4543","AGIX","GDP","SG9999001176.SGD","SG9999013999.USD","BLOK","BK4528","ARTY","BK4213","BK4504","SG9999001176.USD","BK4567","BK4585","BK4587","IE00BFXG0V08.USD","AIYY","IE00BYQQ9H92.USD","BK4082","SGXZ57979304.SGD","AIPO","BK4588","IE00BN0W2W23.USD","BK4551","BK4023","CHAT","EW","IE00BN0W2V16.EUR","AI","IE00BN0W2T93.GBP","LU0345774391.USD","DTCR","LU0345774631.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170319885","title":"异动解读 | 分析师上调目标价，爱德华兹盘中大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170319885","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170319885?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:43","pubTimestamp":1777038226,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司（股票代码：EW）今日盘中股价大幅上涨5.26%，引起了市场的广泛关注。消息面上，多家华尔街分析师发布了关于该公司的研究报告并调整了目标价。其中，瑞穗证券将爱德华兹生命科学公司的目标价从95美元上调至100美元，Truist证券也将目标价从89美元上调至90美元。分析师上调目标价通常反映了对公司未来业绩的乐观预期，这被认为是推动股价上涨的主要动力。尽管康科德金融将其目标价从87美元小幅下调至85美元，但市场整体反应积极，显示出投资者更看重积极的分析师观点。这些分析师评级调整共同影响了市场情绪，带动了爱德华兹股价在交易时段内的显著上扬。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158056026","title":"异动解读 | 爱德华兹盘前大涨5.24%，因瑞穗证券上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1158056026","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158056026?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:40","pubTimestamp":1777034437,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司今日盘前股价大幅上涨5.24%，引起了市场的关注。消息面上，根据华尔街分析师发布的研究报告，瑞穗证券将爱德华兹生命科学公司的目标价从95美元上调至100美元，同时Truist证券也将目标价从89美元上调至90美元。分析师上调目标价通常反映了对公司未来业绩的乐观预期，这可能是推动股价上涨的主要原因。尽管康科德金融将目标价从87美元小幅下调至85美元，但市场整体反应积极，显示出投资者更看重积极的分析师观点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168620005","title":"爱德华兹生命科学公司上调全年调整后每股收益指引中值 新区间定为2.95至3.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168620005","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168620005?lang=zh_cn&edition=full","pubTime":"2026-04-24 04:41","pubTimestamp":1776976901,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司宣布调整其全年财务指引，将调整后每股收益的预测区间更新为2.95美元至3.05美元。这一调整使得指引范围的中值得到显著提升。\n此次上调反映出公司对核心业务增长的强劲信心，尤其是在结构性心脏病创新疗法领域的市场表现超出预期。新指引区间较先前预测有所扩大，为投资者提供了更明确的盈利预期框架。\n公司管理层强调，这一调整基于当前业务势头及产品管线进展，同时考虑了全球医疗市场动态变化。持续的技术创新和临床需求增长成为推动业绩向好的关键动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774391.USD","IE00BN0W2W23.USD","BK4585","BK4504","IE00BN0W2V16.EUR","LU0345774631.USD","IE00BYQQ9H92.USD","SGXZ57979304.SGD","SG9999013999.USD","EW","IE00BN0W2T93.GBP","IE00BFXG0V08.USD","SG9999001176.USD","SG9999001176.SGD","BK4082","BK4588","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174053798","title":"财报前瞻｜爱德华兹本季度营收预计增13.92%，毛利率与净利率指引待披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1174053798","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174053798?lang=zh_cn&edition=full","pubTime":"2026-04-17 00:12","pubTimestamp":1776355929,"startTime":"0","endTime":"0","summary":"市场一致预期显示，本季度爱德华兹收入预计为15.96亿美元，同比增长13.92%，EBIT预计为4.67亿美元，同比增长22.10%，调整后每股收益预计为0.73美元，同比增长21.77%；本季度毛利率与净利润或净利率的一致预期未见披露，暂不展示并以公司正式口径为准。上季度公司营收15.70亿美元，同比增长13.26%；毛利率78.15%；归属于母公司股东的净利润9,120.00万美元，净利率5.81%；调整后每股收益0.58美元，同比下降1.70%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜爱德华兹本季度营收预计增13.92%，毛利率与净利率指引待披露","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614099362","title":"Edwards Lifesciences旗下心血管耗材类产品获FDA批准，注册证号为P150048 S097","url":"https://stock-news.laohu8.com/highlight/detail?id=2614099362","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614099362?lang=zh_cn&edition=full","pubTime":"2026-02-26 13:54","pubTimestamp":1772085240,"startTime":"0","endTime":"0","summary":"产品名称：TRIFORMIS RESILIA Tricuspid Valve, Model 11300T，所属单位：Edwards Lifesciences，产品类型：心血管耗材，产品详情：TRIFORMIS RESILIA Tricuspid Valve, 型号11300T是一种带支架三叶式人工心脏瓣膜，采用RESILIA 牛心包组织制成。审批机构：FDA，证件类型：三类，注册证编号：P150048 S097，获批时间：2026-02-06","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226135423a4ca1f23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226135423a4ca1f23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999013999.USD","BK4588","IE00BN0W2V16.EUR","EW","LU0345774391.USD","IE00BN0W2W23.USD","IE00BYQQ9H92.USD","LU0345774631.USD","BK4504","SG9999001176.USD","SGXZ57979304.SGD","IE00BN0W2T93.GBP","IE00BFXG0V08.USD","BK4567","BK4082","SG9999001176.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512998291","title":"爱德华兹生命科学：2024年业绩符合市场预期 关注新品放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2512998291","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512998291?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:00","pubTimestamp":1739721600,"startTime":"0","endTime":"0","summary":"2024 年业绩符合市场预期公司公布2024 全年业绩：剔除剥离业务后，收入54.40 亿美元，同比+8.6%；经调整EPS 2.43 美元，2023 年同口径为2.22 美元。公司表示12024 年全球范围内竞争格局和产品单价维持稳定，公司预计2025 年TAVR 收入同比增长5-7%。2024 全年,TMTT收入3.52 亿美元，同比+78%；其中4 季度收入1.05 亿美元，环比+15%，同比+88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217105125abd1a46d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217105125abd1a46d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","BK4567","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","BK4082","IE00BYQQ9H92.USD","EW","IE00BFXG0V08.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511246075","title":"巴克莱：维持Edwards Lifesciences(EW.US)评级，由增持调整至增持评级, 目标价由88.00美元调整至90.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511246075","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511246075?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:42","pubTimestamp":1739461331,"startTime":"0","endTime":"0","summary":"巴克莱：维持Edwards Lifesciences(EW.US)评级，由增持调整至增持评级, 目标价由88.00美元调整至90.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13234248149780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110115529","title":"异动解读 | 爱德华公司业绩超预期,主导产品需求旺盛,股价盘中大涨5.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110115529","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110115529?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:40","pubTimestamp":1739371242,"startTime":"0","endTime":"0","summary":"医疗设备制造商爱德华生命科学公司(EW)今日盘中大涨5.93%,引发市场关注。\n公司旗舰产品TAVR设备第四季度销售额高达10.4亿美元,超过市场预期。这一主导产品的需求旺盛,推动公司第四季度整体业绩表现优于市场预期,成为推动该股上涨的主因。\n同时,多家分析师考虑到TAVR潜在保险覆盖范围扩大、手术批准范围加大,以及新产品Sapien M3获批上市等利好因素,上调了对该公司的评级,这也使投资者对其长期发展前景更加看好,进一步推升股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 爱德华公司业绩超预期,主导产品需求旺盛,股价盘中大涨5.93%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edwards.com","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":0.0642},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.1255},{"period":"1year","weight":0.1063},{"period":"ytd","weight":0.0533}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"爱德华兹生命科学公司于1999年9月10日在特拉华州注册成立。公司在结构性心脏病以及重症监护和外科监护方面处于全球领先地位。在帮助患者的热情驱使下，公司与世界领先的临床医生和研究人员合作，投资研发，以改变对结构性心脏病患者的护理，或在手术或重症监护期间需要血流动力学监测的患者的护理。","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.018112},{"month":2,"riseRate":0.576923,"avgChangeRate":0.014785},{"month":3,"riseRate":0.72,"avgChangeRate":0.019095},{"month":4,"riseRate":0.653846,"avgChangeRate":0.033225},{"month":5,"riseRate":0.740741,"avgChangeRate":0.032795},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035042},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002065},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018921},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.008871},{"month":10,"riseRate":0.5,"avgChangeRate":-0.02835},{"month":11,"riseRate":0.692308,"avgChangeRate":0.033175},{"month":12,"riseRate":0.615385,"avgChangeRate":0.042291}],"exchange":"NYSE","name":"爱德华兹","nameEN":"Edwards Lifesciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供爱德华兹(EW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"爱德华兹,EW,爱德华兹股票,爱德华兹股票老虎,爱德华兹股票老虎国际,爱德华兹行情,爱德华兹股票行情,爱德华兹股价,爱德华兹股市,爱德华兹股票价格,爱德华兹股票交易,爱德华兹股票购买,爱德华兹股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供爱德华兹(EW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}